Scientists Target FVIII Inhibitor Formation in Hemophilia A

Scientists Target FVIII Inhibitor Formation in Hemophilia A

292393

Scientists Target FVIII Inhibitor Formation in Hemophilia A

Scientists found the immune signaling protein BAFF can promote the formation of neutralizing antibodies, or inhibitors, against blood clotting factor VIII (FVIII), which can lower the effectiveness of FVIII replacement therapies used to treat people with hemophilia A.  They also discovered that hemophilia A patients who developed anti-FVIII inhibitors had higher BAFF levels in their bloodstream. According to researchers, the findings also support further investigation into the potential treatment combination of rituximab, a B-cell-depleting therapy…

You must be logged in to read/download the full post.